

BIOMARKERS AND THERAPY

SESSION CHAIR: Chee-Yeun Chung, Ph.D.—Yumanity Therapeutics

- 2:15 p.m. Katie Kopil, Ph.D. – The Michael J. Fox Foundation for Parkinson's Research, USA
Alpha-synuclein as a disease biomarker
- 2:45 p.m. Chester Mathis, Ph.D. – University of Pittsburgh, USA
Alpha-synuclein imaging ligands
- 3:15 p.m. Break
- 3:40 p.m. DataBlitz IV
Vivek K. Unni, M.D., Ph.D. – Oregon Health & Science University, USA
In vivo imaging demonstrates progressive aggregation of alpha-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of Parkinsonism
- 3:50 p.m. Richard Fisher, Ph.D. – NeuroPhage Pharmaceuticals, Inc., USA
Novel strategies to target misfolded alpha-synuclein
- 4:20 p.m. Eliezer Masliah, M.D. – University of California, San Diego, USA
Alpha-synuclein immunotherapy
- 4:50 p.m. Discussion
- 5:05 p.m. Closing Remarks

Thank you to our sponsors!



abbvie



custar



Inspired by patients.
Driven by science.



MERCY HEALTH



Lundbeck



Medtronic



SYNTHOS INC.
First Commercial Drug Approved

NeuroPhage
PHARMACEUTICALS



GRAND CHALLENGES IN PARKINSON'S DISEASE

THE ROLE OF ALPHA-SYNUCLEIN | VAN ANDEL RESEARCH INSTITUTE

September 30–October 1, 2015



Wednesday, September 30, 2015

- 7:30 a.m. Continental Breakfast
- 8:30 a.m. Introduction of Keynote Speakers
Peter Jones, Ph.D., D.Sc. – Van Andel Research Institute, USA
- 8:40 a.m. Maria Grazia Spillantini, Ph.D., FMedSci, FRS – University of Cambridge, UK
Jay Van Andel Award for Outstanding Achievement in Parkinson's Disease Research
Alpha-synuclein and its dysfunction in Parkinson's disease
- 9:15 a.m. Robert Nussbaum, M.D., FACP, FACMG – University of California, San Francisco, USA
Jay Van Andel Award for Outstanding Achievement in Parkinson's Disease Research
Parkinson's disease is a systematic illness: A new, emerging paradigm
- 9:45 a.m. Discussion
- 9:55 a.m. Break

ALPHA-SYNUCLEIN CONFORMATION AND FUNCTION

SESSION CHAIR: Jiyang Ma, Ph.D.—Van Andel Research Institute

- 10:20 a.m. Sreeranga Chandra, Ph.D. – Yale School of Medicine, USA
Normal alpha-synuclein function
- 10:50 a.m. Ronald Melki, Ph.D – Neuroscience Paris-Saclay Institute, France
Biophysical characteristics and factors influencing alpha-synuclein aggregation
- 11:20 a.m. Discussion
- 11:35 a.m. DataBlitz I
Daniel Ysselstein – Purdue University
Impaired alpha-synuclein membrane interaction promotes aggregation and neurotoxicity in Parkinson's disease
- 11:45 a.m. Lunch (Patient Discussion 12:00–12:45 p.m.)

PATHOBIOLOGY I

SESSION CHAIR: Sreeranga Chandra, Ph.D.—Yale School of Medicine

- 1:00 p.m. Andrew Singleton, Ph.D. – National Institutes of Health, USA
Alpha-synuclein genetics and disease
- 1:30 p.m. Dennis Dickson, M.D. – Mayo Clinic, USA
Neuropathology in alpha-synucleinopathies
- 2:00 p.m. Tom Beach, M.D., Ph.D. – Banner Sun Health Research Institute, USA
Alpha-synuclein aggregation in peripheral tissues
- 2:30 p.m. Discussion
- 2:45 p.m. Break

PATHOBIOLOGY II

SESSION CHAIR: Darren Moore, Ph.D. — Van Andel Research Institute

- 3:10 p.m. Hilal Lashuel, Ph.D. – École Polytechnique Fédérale de Lausanne, Switzerland
Qatar Biomedical Research Institute, Qatar
Posttranslational modifications of alpha-synuclein

- 3:40 p.m. Michael Lee, Ph.D. – University of Minnesota, USA
The role of intracellular processing in the toxicity of alpha-synuclein
- 4:10 p.m. David Klenerman, Ph.D., FRS – University of Cambridge, UK
Conformational changes associated with toxicity and alpha-synuclein
- 4:40 p.m. DataBlitz II
Evangelia Emmanouilidou, Ph.D. – Biomedical Research Foundation of the Academy of Athens
Gaba transmission via sur1-katp channels regulates alpha-synuclein secretion in mouse striatum
- 4:50 p.m. Discussion
- 5:15 p.m. Poster Session

Thursday, October 1, 2015

- 7:30 a.m. Continental Breakfast

PATHOBIOLOGY III

SESSION CHAIR: John Q. Trojanowski, M.D., Ph.D.—University of Pennsylvania

- 8:30 a.m. Dennis J. Selkoe, M.D. – Harvard Medical School; Brigham and Women's Hospital, USA
A new mechanism of alpha-synuclein-induced neurotoxicity: Tetramer-to-monomer conversion
- 9:00 a.m. Chee-Yeun Chung, Ph.D. – Yumanity Therapeutics, USA
Genetic and physical landscape of alpha-synuclein toxicity
- 9:30 a.m. Ana-Maria Cuervo, M.D., Ph.D. – Albert Einstein College of Medicine of Yeshiva University, USA
Alpha-synuclein degradation
- 10:00 a.m. Discussion
- 10:15 a.m. Break

PATHOBIOLOGY IV

SESSION CHAIR: Jeffrey Kordower, Ph.D.—Rush University Medical Center

- 10:40 a.m. Dimitri Krainc, M.D. – Northwestern University, USA
Interactions between alpha-synuclein and other genes associated with Parkinson's disease
- 11:10 a.m. Virginia Lee, Ph.D. – University of Pennsylvania, USA
Alpha-synuclein cell-to-cell transfer
- 11:40 a.m. Patrik Brundin, M.D., Ph.D. – Van Andel Research Institute, USA
Cell and animal models to study the prion-like behavior of alpha-synuclein
- 12:10 p.m. DataBlitz III
Amanda L. Woerman, Ph.D. – University of California, San Francisco
Identification of alpha-synuclein prions in multiple system atrophy
- 12:20 p.m. Discussion
- 12:35 p.m. Lunch (Patient Discussion 12:45–1:30 p.m.)
- 1:45 p.m. Report from Rallying to the Challenge
Applying the right measure to the right person in the right situation